Earnings summaries and quarterly performance for Adagio Medical Holdings.
Executive leadership at Adagio Medical Holdings.
Board of directors at Adagio Medical Holdings.
Research analysts covering Adagio Medical Holdings.
Recent press releases and 8-K filings for ADGM.
Adagio Medical to Present at Small Cap Growth Virtual Investor Conference
ADGM
Board Change
New Projects/Investments
Debt Issuance
- Adagio Medical Holdings (ADGM) management will present live at the Small Cap Growth Virtual Investor Conference on February 5, 2026, at 1:30 PM ET.
- The company recently appointed Sean Salmon, a former Senior Executive from Medtronic, to its Board of Directors and closed financing of up to $50 million.
- Preliminary acute results from the FULCRUM-VT Pivotal Study highlighted 97% acute effectiveness and favorable safety, with the trial having completed enrollment of 209 patients.
- The results of the FULCRUM-VT study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System.
8 days ago
Adagio Medical Appoints Sean Salmon to Board of Directors
ADGM
Board Change
Hiring
New Projects/Investments
- Adagio Medical Holdings (ADGM) has appointed Sean Salmon to its Board of Directors, where he will also serve on the Audit and Compensation Committees.
- Mr. Salmon brings over 20 years of experience from Medtronic, having served as Executive Vice President and President of Medtronic’s Cardiovascular Portfolio, with extensive expertise in electrophysiology and ablation technologies.
- Adagio is focused on developing proprietary Ultra-Low Temperature Cryoablation (ULTC) technology for cardiac arrhythmias, with its vCLAS™ Cryoablation System commercially available in Europe and undergoing a U.S. Pivotal IDE Trial (FULCRUM-VT) for FDA premarket approval.
Dec 11, 2025, 1:00 PM
Adagio Medical Holdings, Inc. Announces Third Quarter 2025 Results
ADGM
Earnings
CFO Change
Debt Issuance
- Adagio Medical Holdings, Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025.
- The company's cash and cash equivalents totaled $4.7 million as of September 30, 2025.
- A private placement closed on October 20, 2025, providing upfront gross proceeds of approximately $19 million, with potential for up to $31 million in additional gross proceeds.
- Adagio Medical completed enrollment of the 209-patient FULCRUM-VT Pivotal FDA Investigational Device Exemption (IDE) trial, with preliminary results demonstrating 97% acute effectiveness.
- Deborah Kaster was appointed Chief Financial Officer, in addition to her role as Chief Business Officer.
Nov 12, 2025, 9:05 PM
Adagio Medical Closes $19 Million Upfront Financing
ADGM
New Projects/Investments
- Adagio Medical Holdings, Inc. (ADGM) closed a private placement financing of $19 million upfront on October 20, 2025, with participation from existing and new healthcare-dedicated institutional investors.
- The proceeds are designated to fund ongoing development and submission activities for FDA evaluation of the company's proprietary Ultralow Cryoablation Technologies, including the vCLAS™ ULTC System.
- This capital infusion is anticipated to extend the company's cash runway into key inflection points and de-risk execution.
- The FULCRUM-VT pivotal clinical study, crucial for FDA premarket approval of the vCLAS™ Cryoablation System, completed enrollment on October 1, 2025, involving 208 patients.
Oct 20, 2025, 5:04 PM
Adagio Medical Holdings, Inc. Announces Preliminary Acute Results from FULCRUM-VT Study
ADGM
Product Launch
New Projects/Investments
- Adagio Medical Holdings, Inc. announced preliminary acute safety and efficacy results from its FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation (ULTC) for the treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT).
- The study, presented on October 10, 2025, involved 207 patients and demonstrated an acute clinical success rate of 97.4% for non-inducibility of target ventricular arrhythmias.
- All clinically-relevant ventricular tachycardias were eliminated in 96.7% of patients tested by post-ablation programmed electrical stimulation.
- The study reported a 2.5% rate of major adverse events, including four (1.9%) peri-procedural deaths, with one (0.5%) adjudicated as definitely related to the investigational device.
- These results are intended to support the application for FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System.
Oct 10, 2025, 7:41 PM
Adagio Medical Holdings, Inc. Completes Enrollment for FULCRUM-VT Clinical Trial
ADGM
New Projects/Investments
Product Launch
- Adagio Medical Holdings, Inc. (ADGM) announced the completion of enrollment for its FULCRUM-VT Pivotal Clinical Trial on October 1, 2025.
- The trial evaluates the company's vCLAS Cryoablation System for the ablation of monomorphic ventricular tachycardia (MMVT), a system that holds FDA Breakthrough Device Designation.
- The study enrolled 208 patients across 20 centers in the U.S. and Canada, with results intended to support a pre-market approval (PMA) application.
- Adagio anticipates completion of the PMA process for the vCLAS System by year-end 2026.
Oct 1, 2025, 12:01 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more